Using the same cut-off as of training cohort, the individual sensitivity and specificity for cancer detection were 35.0% (21/60) and 91.3% (167/183) for CD24, 35.0% (21/60) and 83.6% (153/183) for CD49f, and 51.7% (31/60) and 88.5% (162/183) for NANOG, respectively (Table 2). The gene discussed is NANOG; the disease is cancer.